Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTLNASDAQ:EUDANASDAQ:INNVNASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$20.30+1.4%$18.01$15.45▼$35.84$587.83M1.1424,766 shs94,350 shsEUDAEUDA Health$3.41-3.1%$3.67$2.92▼$6.30$126.72M-0.0483,268 shs54,176 shsINNVInnovAge$4.27+2.9%$3.75$2.60▼$6.69$570.42M0.5150,537 shs19,706 shsPSNLPersonalis$7.47-0.5%$5.21$1.20▼$7.79$659.75M1.951.05 million shs815,597 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences-1.62%+2.77%+22.99%+4.27%-5.88%EUDAEUDA Health+2.92%-3.83%-3.83%-5.38%-5.63%INNVInnovAge+5.06%+8.64%+6.14%+49.28%-17.50%PSNLPersonalis+14.31%+24.54%+55.49%+127.58%+525.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSTLCastle Biosciences2.7227 of 5 stars3.54.00.00.01.62.50.0EUDAEUDA Health0.7764 of 5 stars0.05.00.00.01.60.00.6INNVInnovAge1.0217 of 5 stars1.82.00.00.02.21.70.6PSNLPersonalis3.2917 of 5 stars1.53.00.04.22.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 3.00Buy$37.0082.31% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/AINNVInnovAge 1.50Reduce$5.0017.10% UpsidePSNLPersonalis 3.00Buy$7.672.63% UpsideCurrent Analyst Ratings BreakdownLatest EUDA, CSTL, PSNL, and INNV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$347.08M1.69$0.98 per share20.67$16.28 per share1.25EUDAEUDA Health$4.01M31.60N/AN/A($0.07) per share-48.71INNVInnovAge$763.85M0.75N/AN/A$2.04 per share2.09PSNLPersonalis$84.61M7.80N/AN/A$2.87 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)EUDAEUDA Health-$15.36MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)INNVInnovAge-$21.34M-$0.23N/A71.17N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)PSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)Latest EUDA, CSTL, PSNL, and INNV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025N/AEUDAEUDA Health-$0.02N/AN/AN/AN/AN/A5/6/2025Q3 2025INNVInnovAge-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AINNVInnovAgeN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.029.379.19EUDAEUDA HealthN/A0.180.15INNVInnovAge0.040.780.78PSNLPersonalisN/A6.916.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%EUDAEUDA Health4.35%INNVInnovAge12.26%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.50%EUDAEUDA HealthN/AINNVInnovAge1.40%PSNLPersonalis3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54028.87 million27.00 millionOptionableEUDAEUDA Health237.16 millionN/ANot OptionableINNVInnovAge2,350135.01 million133.12 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableEUDA, CSTL, PSNL, and INNV HeadlinesRecent News About These CompaniesPersonalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?5 hours ago | zacks.comPersonalis (NASDAQ:PSNL) Hits New 12-Month High - Here's WhyJuly 2 at 2:35 PM | marketbeat.comPersonalis (NASDAQ:PSNL) Trading 6.4% Higher - Should You Buy?June 30 at 1:20 PM | marketbeat.comThe 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394%June 18, 2025 | finance.yahoo.comPersonalis (NASDAQ:PSNL) Shares Up 7% - Should You Buy?June 18, 2025 | marketbeat.comPersonalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?June 17, 2025 | zacks.comPersonalis (NASDAQ:PSNL) Stock Price Up 7.4% - Time to Buy?June 11, 2025 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Buy" from BrokeragesJune 9, 2025 | marketbeat.comPersonalis: Ultra-Sensitive Tech, Ultra-Sensitive RisksJune 8, 2025 | seekingalpha.comPersonalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LPJune 7, 2025 | marketbeat.comPersonalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 4, 2025 | finance.yahoo.comSquarepoint Ops LLC Has $530,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)June 4, 2025 | marketbeat.comPersonalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOJune 3, 2025 | businesswire.comPersonalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-TherapyJune 3, 2025 | insidermonkey.comNew Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for RelapseJune 2, 2025 | finance.yahoo.comNew Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for RelapseJune 2, 2025 | businesswire.comPersonalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence DetectionMay 22, 2025 | finance.yahoo.comNasdaq Composite Personalis (NASDAQ:PSNL) Advances Precision Medicine GloballyMay 15, 2025 | kalkinemedia.comKCompanies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In GrowthMay 8, 2025 | finance.yahoo.comPersonalis Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comPersonalis, Inc. (PSNL) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEUDA, CSTL, PSNL, and INNV Company DescriptionsCastle Biosciences NASDAQ:CSTL$20.30 +0.29 (+1.42%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.EUDA Health NASDAQ:EUDA$3.41 -0.11 (-3.13%) As of 12:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.InnovAge NASDAQ:INNV$4.27 +0.12 (+2.89%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.Personalis NASDAQ:PSNL$7.47 -0.04 (-0.53%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
